Kangji Healthcare (09997) announced its annual results for the year ended December 31, 2023, with revenue of 926 million yuan (...
According to the Zhitong Finance App, Kangji Healthcare (09997) announced results for the year ended December 31, 2023, with revenue of 926 million yuan (RMB, same below), up 17.8% year on year; profit attributable to parent company owners was 504 million yuan, up 5.3% year on year; basic profit per share was 43.08 points.
The increase in sales during the period was mainly due to a steady increase in sales in the domestic market as the number of elective surgeries gradually resumed after COVID-19 prevention restrictions were relaxed. The Group's export sales also grew rapidly, thanks to the Group's development of more distributors in new regions.
The increase in net profit attributable to the Group's parent company owners during the reporting period was mainly due to an increase in the Group's sales, but was partially offset by increased research and development expenses of the Group and its subsidiary Hangzhou Weijing Medical Robotics Co., Ltd. and increased income tax expenses for dividend withholding tax.
In addition, the board of directors has decided to recommend the payment of a final dividend of RMB 41 points per share of the company's common share and a special dividend of RMB 99 points per share for the year ended 31 December 2023 to celebrate the 20th anniversary of the establishment of the Group and return the long-term support of the company's shareholders.